Optimizing Organoid Models to Better Predict Clinical Outcomes
One of the most promising aspects of research using organoid models is the possibility to screen cultures derived from individual patient tissue samples to better predict clinical outcomes. In this webinar, Dr. Sylvia Boj (HUB Organoids) and Dr. Martin Stahl (STEMCELL Technologies) discussed the products, protocols, and assays that enable the use of organoid models in drug discovery research, with a focus on intestinal and liver organoids. First, Dr. Boj presented an overview of patient-derived organoid models curated by the HUB and how they can be used to predict gastrointestinal and liver drug-induced toxicity. Following this, Dr. Stahl described the functional benefits of IntestiCult™ cell culture applications for drug development and the resulting effects on cell viability, proliferation, epithelial integrity, and barrier function.
Publish Date:
July 06, 2023
Request Pricing
Thank you for your interest in this product. Please provide us with your contact information and your local representative will contact you with a customized quote. Where appropriate, they can also assist you with a(n):
Estimated delivery time for your area
Product sample or exclusive offer
In-lab demonstration
By submitting this form, you are providing your consent to STEMCELL Technologies Canada Inc. and its subsidiaries and affiliates (“STEMCELL”) to collect and use your information, and send you newsletters and emails in accordance with our privacy policy. Please contact us with any questions that you may have. You can unsubscribe or change your email preferences at any time.